Demethylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome

Molecular Human Reproduction

Volumn 16, Issue 4, 2009, Pages 260-266

  Zhu, Jia Qiao ^a,b   Zhu, Liang ^c   Liang, Xing Wei ^a   Xing, Fu Qi ^c   Schatten, Heide ^d   Sun, Qing Yuan ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b YANGZHOU UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

DNA demethylation; LHR; Polycystic ovary syndrome

Indexed keywords

ANDROGEN RECEPTOR; FOLLITROPIN RECEPTOR; LUTEINIZING HORMONE RECEPTOR; PRASTERONE; RNA H19; TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAG REPEAT; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNA RESTRICTION; DNA SEQUENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; FEMALE; GENETICS; POLYMERASE CHAIN REACTION;

ANIMALS; DEHYDROEPIANDROSTERONE; DISEASE MODELS, ANIMAL; DNA METHYLATION; FEMALE; MICE; POLYCYSTIC OVARY SYNDROME; POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; RECEPTORS, FSH; RECEPTORS, LH;

EID: 77952779185     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gap089     Document Type: Article

References (47)

1. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol 2002;174:1-5.
2. Anderson E, Lee MT, Lee GY. Cystogenesis of the ovarian antral follicle of the rat: ultrastructural changes and hormonal profile following the administration of dehydroepiandrosterone. Anat Rec 1992; 234:359-382.
3. Aragno M, Brignardello E, Tamagno E, Gatto V, Danni O, Boccuzzi G. Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats. J Endocrinol 1997; 155:233-240.
4. Aragno M, Mastrocola R, Brignardello E, Catalano M, Robino G, Manti R, Parola M, Danni O, Boccuzzi G. Dehydroepiandrosterone modulates nuclear factor-kappa B activation in hippocampus of diabetic rats. Endocrinology 2002;143:3250-3258.
5. Azziz R, Kashar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000;13:1303-1306.
6. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999;99:451-454.
7. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899.
8. Colot V, Rossignol JL. Eukaryotic DNA methylation as an evolutionary device. Bioessays 1999;21:402-411.
9. Davis TL, Yang GJ, McCarrey JR, Bartolomei MS. The H19 methylation imprint is erased and re-established differentially on the parental alleles during male germ cell development. Hum Mol Genet 2000; 9:2885-2894.
10. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007; 8:127-141.
11. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
12. El-Hefnawy T, Krawczyk Z, Nikula H, Vihera I, Huhtaniemi I. Regulation of function of the murine luteinizing hormone receptor promoter by cis- and trans-acting elements in mouse Leydig tumor cells. Mol Cell Endocrinol 1996;119:207-217.
13. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C, Motta AB. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 2006;12:475-481.
14. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:251-282.
15. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604-10609.
16. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
17. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12:2641-2648.
18. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol 2000;163:49-52.
19. Griswold MD, Kim JS. Site-specific methylation of the promoter alters deoxyribonucleic acid-protein interactions and prevents follicle-stimulating hormone receptor gene transcription. Biol Reprod 2001; 64:602-610.
20. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-165.
21. Hickey TE, Legro RS, Norman RJ. Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:2789-2791.
22. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001; 86:1318-1323.
23. Kahsar-Miller M, Azziz R. The development of the polycystic ovary syndrome: family history as a risk factor. Trends Endocrinol Metab 1998;9:55-58.
24. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001;75:53-58.
25. Kucharski R, Maleszka J, Foret S, Maleszka R. Nutritional control of reproductive status in honeybees via DNA methylation. Science 2008; 319:1827-1830.
26. Kuijper EA, Vink JM, Lambalk CB, Boomsma DI. Prevalence of polycystic ovary syndrome in women from opposite-sex twin pairs. J Clin Endocrinol Metab 2009;94:1987-1990.
27. Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anat Rec 1991;231:185-192.
28. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998a;95:14956-14960.
29. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF 3rd, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 1998b;53:217-256.
30. Lei ZM, Mishra S, Zou W, Xu B, Foltz M, Li X, Rao CV. Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene. Mol Endocrinol 2001;15:184-200.
31. Liang XW, Zhu JQ, Miao YL, Liu JH, Wei L, Lu SS, Hou Y, Schatten H, Lu KH, Sun QY. Loss of methylation imprint of Snrpn in postovulatory aging mouse oocyte. Biochem Biophys Res Commun 2008;371:16-21.
32. Longcope C. Dehydroepiandrosterone metabolism. J Endocrinol 1996; 150:S125-S127.
33. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, Chiocchio S, Cremaschi G, Motta AB. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol 2004;64:59-74.
34. Lucifero D, Mertineit C, Clarke HJ, Bestor TH, Trasler JM. Methylation dynamics of imprinted genes in mouse germ cells. Genomics 2002; 79:530-538.
35. Meaney MJ, Szyf M, Seckl JR. Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health. Trends Mol Med 2007;13:269-277.
36. Nikula H, Koskimies P, El-Hefnawy T, Huhtaniemi I. Functional characterization of the basal promoter of the murine LH receptor gene in immortalized mouse Leydig tumor cells. J Mol Endocrinol 2001; 26:21-29.
37. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008;3:97-106.
38. Rao CV, Lei ZM. Consequences of targeted inactivation of LH receptors. Mol Cell Endocrinol 2002;187:57-67.
39. Sander V, Luchetti CG, Solano ME, Elia E, Di Girolamo G, Gonzalez C, Motta AB. Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction 2006;131:591-602.
40. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd, Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 1999;96:8573-8578.
41. Vottero A, Stratakis CA, Ghizzoni L, Longui CA, Karl M, Chrousos GP. Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. J Clin Endocrinol Metab 1999;84:1091-1095.
42. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988;66:165-172.
43. Warnecke PM, Mann JR, Frommer M, Clark SJ. Bisulfite sequencing in preimplantation embryos: DNA methylation profile of the upstream region of the mouse imprinted H19 gene. Genomics 1998;51:182-190.
44. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84:2951-2956.
45. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999;286:481-486.
46. Zhang FP, Poutanen M, Wilbertz J, Huhtaniemi I. Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. Mol Endocrinol 2001;15:172-183.
47. Zhang Y, Fatima N, Dufau ML. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription. Mol Cell Biol 2005; 25:7929-7939.